Introduction
============

Lung adenocarcinoma is the most common form of lung cancer and it belongs to the histologic subgroup of non-small cell lung cancer ([@b1-ol-0-0-6481],[@b2-ol-0-0-6481]). This cancer type grows slowly but can undergo hematogenous metastasis at an early stage. The prognosis for survival is poorer for lung adenocarcinoma than squamous carcinoma, and its 5-year survival rate after surgical removal is less than 10% ([@b3-ol-0-0-6481]--[@b6-ol-0-0-6481]). In the United States, almost 40% of lung cancers are adenocarcinoma and usually originate from the surrounding lung tissue. The incidence of lung adenocarcinoma varies with age, and is more common among female subjects. The number of newly diagnosed cases has been on the increase in many western developed countries in recent decades, and it now constitutes the most common type of lung cancer among smokers, replacing squamous cell lung cancer ([@b7-ol-0-0-6481]--[@b9-ol-0-0-6481]).

A microRNA (miRNA) is a short single highly-conserved non-coding RNA that is important in the expression and functional regulation of eukaryotic genomes (e.g., proliferation, apoptosis, migration and angiogenesis) and these biological processes are integral for tumor formation and development ([@b10-ol-0-0-6481]--[@b12-ol-0-0-6481]). miR-378 ([@b11-ol-0-0-6481]) inhibits migration and invasion of prostate cancer cell, and promotes apoptosis. In addition, Zhou *et al* ([@b13-ol-0-0-6481]) found that miR-590-5p inhibited breast cancer cells, thereby providing a novel therapeutic approach for breast cancer patients. The Cancer Genome Atlas (TCGA), is an existing relatively authoritative sequencing database, that contains a variety of common tumors ([@b14-ol-0-0-6481]). The purpose of this database is to better understand the molecular basis of cancer through the application of genome analysis technologies, identifying mutations in DNA sequence, copy number variation and alterations in methylation status.

The aim of the present study was to combine partial genomic data to determine the prognosis of patients with lung adenocarcinoma.

Materials and methods
=====================

### miRNA and patient data

Level 3 data of miRNA expression profile and the corresponding clinical data were downloaded from the TCGA ([@b14-ol-0-0-6481]). All the data were publically available. The downloaded miRNA expression data and clinical data were integrated, and patients with lung adenocarcinoma were selected for inclusion. Patients with lung adenocarcinoma whose age was unknown and those whose survival time was \<30 days were excluded.

The downloaded data from TCGA included tissue miRNA data from 521 patients with lung adenocarcinoma and miRNA expression data of 46 cases of para-carcinoma tissue. To screen differentially expressed miRNA, the selection criteria were set to be log fold change \>1 and P\<0.05. The up- and downregulated expression of miRNA in lung adenocarcinoma tissue was screened, and standardized treatment was conducted on the miRNA expression. In addition, the thermograph of tissue miRNA expression of patients with lung adenocarcinoma was drawn through pheatmap R of software R ([@b15-ol-0-0-6481]).

### Establishment of prognostic model

To construct the prognosis model focusing on miRNA for lung adenocarcinoma, a log2 transform was conducted on the expression level of miRNA. A total of 478 cases with lung adenocarcinoma were randomly divided into either the training or test set, and the Chi-square test was applied to test whether there was statistical significance at each stage from the two sets (P\<0.05). The miRNA that was closely associated with survival time of the patients in the training set were selected through univariate Cox proportional hazards regression (P\<0.001). Next, miRNA was constructed into the prognostic model with the multivariate Cox regression. The optimal prognostic model was selected based on the Akaike information criterion ([@b16-ol-0-0-6481]). The median value of the model of the training set was regarded as the cut-off value, and the patients with lung adenocarcinoma in the training set were divided into either the high-risk or low-risk group. A Kaplan-Meier (KM) survival plot was constructed and if P\<0.05 (the model was established in the training set) the model was entered into the verification set. The median value of the training set model was regarded as the cut-off value. In addition, the patients with lung adenocarcinoma in the verification set were divided into high- or low-risk groups. KM survival curve was constructed and if P\<0.05, it showed that the prognosis model was established. After the model was established, KM survival curves were respectively drawn for various subgroups (e.g., male vs. female, age \>65 or ≤65 years, type of treatment). Then, receiver operating characteristic (ROC) curve of 5-year survival rate of subgroups was drawn using the ROC package of software R ([@b17-ol-0-0-6481]).

### Cox regression

A single factor Cox regression was used to evaluate the relationship between clinical characteristics and survival time of patients with lung adenocarcinoma. The clinical features that were closely related to the survival were screened, and they, together with prognosis model were analyzed using multivariate Cox regression model to explore whether the prognosis model could be used as an independent predictor of patients prognosis with lung adenocarcinoma.

Results
=======

A total of 1,881 miRNA expression spectrum (level 3) data of 521 patients with lung adenocarcinoma tissue and 46 cases of para-carcinoma tissue were downloaded from TCGA. A total of 309 differentially expressed miRNAs were screened, including 188 upregulated miRNAs and 121 downregulated miRNAs ([Fig. 1](#f1-ol-0-0-6481){ref-type="fig"}). hsa-miR-210, hsa-miR-708 and hsa-miR-96 were the three most significantly upregulated miRNAs, while hsa-miR-486-1, hsa-miR-486-2 and hsa-miR-4732 were the three most significantly downregulated miRNAs. According to the inclusion criteria, the data from 478 patients with lung adenocarcinoma were analyzed. These patients were sub-divided into the training (n=239) or test set (n=239), based on the principle of random distribution ([Table I](#tI-ol-0-0-6481){ref-type="table"}). There was no statistical difference between the stages from the training or validation set (P\>0.05).

For the prognosis model constructed in the present study, the prognostic score = 44.488 × (expression quantity of hsa-miR-101-1) - 1.673 × (expression quantity of hsa-miR-200a) + 0.428 × (expression quantity of hsa-miR-4661) + 0.515 × (expression quantity of hsa-miR-450a-2). Of the four miRNAs, hsa-miR-4661 and hsa-miR-4661 had an upregulated expression, while hsa-miR-101-1 and hsa-miR-200a had a downregulated expression. The significance (P-value) from the KM survival curve of the prognostic model in the training set, the validation set, and the total number of patients, was 0.01986 ([Fig. 2](#f2-ol-0-0-6481){ref-type="fig"}), 0.02773 ([Fig. 3](#f3-ol-0-0-6481){ref-type="fig"}) and 0.0017 ([Fig. 4](#f4-ol-0-0-6481){ref-type="fig"}), respectively, showing that the high-risk group of lung adenocarcinoma patients in the model had a shorter survival time than low-risk group. In addition, the model assessed each subgroup. The statistical significance (P-values) from the KM survival curve of the male, female, treatment, non-treatment, Caucasian group and non-Caucasian groups was 0.04055, 0.01487, 0.65091, 0.00088, 0.00043 and 0.60825, respectively ([Figs. 2](#f2-ol-0-0-6481){ref-type="fig"}--[4](#f4-ol-0-0-6481){ref-type="fig"}). In the present study, only the ROC curve of the 5-year survival rate of the subgroups which KM survival curve P\<0.05 was utilized. The results showed that the prognosis model had the best diagnostic performance in the Caucasian group, with the area under the curve AUC=0.629; AUC of male group, female group and non-treatment group was 0.595, 0.592 and 0.579 respectively.

In addition, the analysis through the single factor Cox regression showed that pathologic stages (P=2.22E-08), pathology N stages (P=2.52E-07), and pathology T stages (P=0.0007) were closely related to the survival of patients with lung adenocarcinoma ([Table II](#tII-ol-0-0-6481){ref-type="table"}). Multivariable Cox regression showed both the prognosis model (P=0.005) and age (P=0.03) were independent prognostic variable models of lung adenocarcinoma ([Table II](#tII-ol-0-0-6481){ref-type="table"}). However, the prognosis model constructed in the study was superior to the assessment of the survival of patients with lung adenocarcinoma with age.

Discussion
==========

By constructing a prognosis model focusing on four miRNAs, patients with lung adenocarcinoma were divided into a high- or low-risk group, and the survival time of the high-risk group was shown to be less than that of low-risk group. After constructing a multivariable Cox regression model using patient clinical characteristics, the results showed that the prognosis model serves as a potential independent prognostic model to assess the survival time of patients with lung adenocarcinoma (P=0.005). The prognostic model had a general assessment effect on the treatment (P=0.65091) and non-Caucasian (P=0.60825) groups, but were underpowered due to too few patients in the two groups. The prognostic model showed a good assessment effect on the non-treatment and Caucasian groups, and it could also predict the 5-year survival rate of patients with lung adenocarcinoma of the Caucasian group (AUC=0.629). As the majority of the data in TCGA included Caucasian patients, and contained data from only a relatively smaller proportion from other ethnicities, the conclusions drawn from the present study are more applicable to Caucasian patients.

The prognostic model from the present study utilized the miRNAs hsa-miR-101-1, hsa-miR-200a, hsa-miR-4661 and hsa-miR-450a-2. Chang *et al* ([@b18-ol-0-0-6481]) showed that hsa-miR-200a was downregulated in patients with gastric cancer, and could be used as a potential biomarker to predict the survival and prognosis of patients with gastric cancer. In the present study, there was an upregulated expression of hsa-miR-200a miRNA in lung adenocarcinoma tissue samples, indicating a differential regulation of the same miRNA from these different tumors. Liu *et al* ([@b19-ol-0-0-6481]) demonstrated that the expression of miR-101 in breast cancer could lead to E-cadherin downregulation, and miR-101 may inhibit the expression of DNMT3A and the proliferation and migration of human breast adenocarcinoma MDA-MB-231 cells. Furthermore, hsa-miR-101 is involved in a wide variety of other tumor processes \[e.g., pancreatic cancer ([@b20-ol-0-0-6481]) and hepatocellular carcinoma ([@b21-ol-0-0-6481])\]. Other findings showed that the downregulated expression of miRNA-450b-3p could lead to the upregulated expression of HER3, thereby affecting the prognosis of patients with breast cancer ([@b22-ol-0-0-6481]). The prognosis model focusing on the four miRNAs constructed in the present study confirmed that the expression of these tissue miRNAs correlated with the survival time of patients with lung adenocarcinoma, and it can be used as an independent prognostic model for prognosis assessment of patients with lung adenocarcinoma.

Although the independent prognosis model for evaluating the patients with lung adenocarcinoma was established in the study, there are limitations. Firstly, all the data in the study were from one database, the TCGA, and the conclusions could be more reliable if they were verified using other independent databases. In addition, the study only included 478 patients with lung adenocarcinoma, and some of the subgroups were underpowered. In conclusion, the prognostic model developed in the present study, focusing on miRNAs, can be used as an independent prognostic model for survival time of patients with lung adenocarcinoma.
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###### 

Patient demographics and tumor characteristics from the training and validation set.

  Covariates                      Total (n=478)   Training set (n=239)   Testing set (n=239)   P-value
  ------------------------------- --------------- ---------------------- --------------------- ---------
  Age (years)                                                                                  0.833
    ≤65                           232             121                    111                   
    \>65                          246             118                    128                   
  Pathological stages                                                                          0.90
    I                             259             134                    125                   
    II                            111               53                     58                  
    III                             78              33                     45                  
    IV                              24              17                     7                   
    NA                              6               2                      4                   
  Pathology T stages                                                                           0.87
    T1                            163               85                     78                  
    T2                            250             121                    129                   
    T3                              44              22                     22                  
    T4                              18              9                      9                   
    Tx                              3               2                      1                   
  Pathology N stages                                                                           0.83
    N0                            309             161                    148                   
    N1                              87              40                     47                  
    N2-N3                           70              32                     38                  
    NX-NA                           12              6                      6                   
  Pathology M stages                                                                           0.91
    M0                            315             155                    160                   
    M1                              23              17                     6                   
    MX                            136               65                     71                  
    NA                              4               2                      2                   
  Sex                                                                                          0.86
    Male                          222             113                    109                   
    Female                        256             126                    130                   
  Radiation therapy                                                                            0.75
    No                            374             192                    182                   
    Yes                             59              24                     35                  
    NA                              45              23                     22                  
  Ethnicity                                                                                    0.86
    Asian                           7               4                      3                   
    Caucasian                     373             191                    182                   
    African or African-American     52              23                     29                  
    NA                              46              21                     25                  
  Status                                                                                       0.79
    Dead                          169               83                     86                  
    Surviving                     309             156                    153                   

NA, not applicable.

###### 

Association of clinical factors and the miRNA signature score with survival time from lung adenocarcinoma patients.

                                                        Univariate analysis   Multivariate analysis          
  ----------------------------------------------------- --------------------- ----------------------- ------ -------
  Age (\>65 vs. ≤65)                                    1.18                  0.307                   1.31   0.03
  Pathologic stages (IV vs. III vs. II vs. I)           1.56                  2.22E-08                       
  Pathology T stages (T4 vs. T3 vs. T2 vs. T1 vs. T0)   1.42                  0.0007                  1.19   0.157
  Pathology N stages (N3 vs. N2 vs. N1 vs. N0)          1.65                  2.52E-07                1.17   0.15
  Sex (male vs. female)                                 1.12                  0.498                          
  Ethnicity (white vs. non-white)                       1.74                  0.211                          
  miRNA model scores (high vs. low score)               2.87                  0.0002                  1.62   0.005

microRNA, miRNA.
